I miss pharma and emperor. Hopefully they will show up in Vegas!!!

Preparing his next trap

Never speculate on this. U don’t want to jinx it.

Nice pinned post - deserves bunch of Thumbs up ::)

Right or left?

As long as his self serving moves serve all the longs I don’t see that as self serving bi see those moves as investors serving moves.

Last time the fake king predicted something good we got a bear raid. Just FYI

The fake king has never been right when bashing Nasrat in my opinion. Nasrat has saved this company and made it the only company trading on the otc that has been profitable in 5 years and growing. The only otc company that in the last 3 years went from 2.5 cents to 70 cents.

Right about what?

Poisoned news imho

Welcome to Elite MONK!!!

This is the spirit !!!

Victory Predicted by Nasrat !!!

There is an AI Tab on Ihub - I asked this simple question:
can you point to manipulative patterns in today's trades performed on ELTP with Examples?
To identify manipulative patterns in today's trades for Elite Pharmaceuticals, Inc. (ELTP), we need to look at intraday trading data, including price movements, trading volumes, and order book activity. Here are some common manipulative patterns and examples of what to look for:

1. Pump and Dump
Pattern: A rapid increase in stock price followed by a sharp decline, often accompanied by high trading volumes.

Example:

Morning: The stock price jumps from $0.50 to $0.70 within an hour, with trading volume spiking significantly.
Afternoon: The stock price suddenly drops back to $0.50, with trading volume decreasing.
2. Wash Trading
Pattern: High trading volumes with little to no change in stock price, indicating trades between colluding parties to create the illusion of activity.

Example:

Throughout the Day: The stock price remains around $0.57, but there are multiple large trades (e.g., 100,000 shares) executed at the same price, creating high volume without price movement.
3. Spoofing
Pattern: Placing large orders with no intention of executing them to create a false sense of demand or supply.

Example:

Order Book: Large buy orders at $0.56 are placed and then quickly canceled before execution, creating the illusion of strong demand.
4. Layering
Pattern: Placing multiple orders at different price levels to manipulate the market depth and create a misleading impression of supply and demand.

Example:

Order Book: Multiple sell orders are placed at $0.58, $0.59, and $0.60, creating the impression of strong resistance, but these orders are canceled as the price approaches.
Steps to Identify Manipulative Patterns:
Retrieve Intraday Trading Data:

Obtain detailed intraday price and volume data for ELTP for today.
Access the order book data to analyze large orders and cancellations.
Analyze the Data:

Look for unusual price movements, volume spikes, and patterns that may indicate manipulation.
Identify any rapid increases in stock price followed by sharp declines.
Check for high trading volumes with minimal price movement.
Analyze the order book for large orders that are quickly canceled or multiple orders at different price levels.
Example Analysis:
To illustrate, let's assume we have the following intraday data for ELTP:

Intraday Price and Volume Data:

Time Price Volume
09:30 0.50 10,000
10:00 0.70 100,000
11:00 0.65 50,000
12:00 0.60 30,000
13:00 0.55 20,000
14:00 0.50 10,000
Order Book Data:

Time Order Type Price Quantity Status
09:30 Buy 0.56 50,000 Canceled
10:00 Buy 0.57 100,000 Canceled
11:00 Sell 0.58 30,000 Canceled
12:00 Sell 0.59 40,000 Canceled
13:00 Sell 0.60 50,000 Canceled
Analysis:
Pump and Dump: The price jumps from $0.50 to $0.70 with high volume at 10:00, then drops back to $0.50 by 14:00, indicating a potential pump and dump.
Wash Trading: High volumes at 10:00 and 11:00 with minimal price movement suggest possible wash trading.
Spoofing: Large buy orders at $0.56 and $0.57 are canceled, indicating potential spoofing.
Layering: Multiple sell orders at $0.58, $0.59, and $0.60 are canceled, indicating potential layering.
Conclusion:
To conclusively identify manipulative patterns, detailed intraday data and order book analysis are essential. If you have access to such data, you can perform a thorough analysis to detect signs of market manipulation.

You need Many many many pulations to be able to do that

Hi SoT

I have one thing to say to those who are not sure Vyvanse is not going to be approved: RTFT:

"Now, two of the three products that I mentioned are needle movers. So let me say a few more words about that. Regarding the CMS application, the FDA asked us to make a couple of minor adjustment. Tighten the spec, move this over here and there, nothing of relevance. But the FDA did request an extra month to review the DMF for the API supplier.

So our PDUFA date is November. That was very nice of FDA to do that, because they found that our application itself doesn’t have any issues or all the issues we had, we resolved them over the past year. They had a question to the DMF supplier, and instead of saying, take this back and call us back in a year or in six months or whatever, they actually said, we need another month to resolve some issues, which is really very promising. And we will update you in November once we hear – if we hear from FDA and what their verdict is."

Spoke to the ELTP Emperor - He says Hi to the board

Since I wrote that we discovered other pieces of the puzzle.

Nasrat also said a while ago that other international opportunities existed but they would be disclosed when they have big orders. Dexcel is international.
The puzzle pieces are coming together.

Freedom is about making the right choices for you

Then Nasrat will take over the job lol

Great we got Insider info !!!

Thanks IB_

-----------------
I agree !!!!!!

Had there been a negative leak concerning Vyvanse, we would be much lower now !!!!!!!!!!

The Bear Raid was to take out Stop Loss Orders and take share from nervous investors ........

They loaded up and now are waiting for the official PR,

IB_🤴

Nasrat mentioned M&A to Buyout ... mmmm

Pranksalot - you forgot to mention BLUE LIVES MATTER

Perfect Match - They acquire ELTP - Nasrat retires

Elite also passed the partnership test

I would add that the EPS went down because of investments - it used to be higher - last quarter we invested a lot in the new facility that we do not use yet. We are limited by the size of our manufacturing and storage plant.

As soon as it is approved, and we increase production and sales the EPS will go up.

--------------

ELTP is still way undervalued according to this calculation.

Drug Manufacturers
Specialty & Generic
P/E ratio: 36.45 current average of
47 generic manufacturers

ELTP EPS ($0.0191)
x Average P/E Ratio by Industry of (36.45) of 47 generic drug manufacturers
= Price Per Share ($0.6962)

ELTP should be at $0.6962 per share even before all these newly revenue to be reported with the recent launches of Methotrexate
(~$63 million market),
Codeine with Acetaminophen
(~$47 million market), and
generic Addera by Dexcel Pharma in Israel.

https://fullratio.com/pe-ratio-by-industry

There will be significantly more revenue reported from the launches of generic Percocet
(~ $500 million market) launching around 11/18/24 and
generic Norco
(~$477 million market) launching probably right after the new year.

Elite will have awesome news soon with another record breaking quarterly earnings press release on 11/14/24 and the approval of generic Vyvanse hopeful in November 2024
($5.1 billion market).

Casual investors will regret giving up their shares so soon recently.

True long ELP investors with do extremely well with their returns when it goes to $5 to $7 within the next 2 years.

Elite’s revenue was ~$56.6 million for the last fiscal year.

Imagine what the share price can be if Elite’s revenue is ~$566 million for all the drugs that are approved for launch and those about to be approved in the pipeline.

10 fold on EPS could be $0.191

$0.191 x 36.45 = $6.962

And this price per share is not even factoring the potential of Elite’s future, Abuse Resistant Technology branded drugs.

1. oxycodone with naltrexone (SequestOx)
2. hydrocodone with naltrexone
3. oxymorphone with naltrexone
4. hydromorphone with naltrexone
5. morphine sulfate with naltrexone

NASDAQ listed is within reach.
Buy out offer is plausible.

My current road map with investing in ELTP.

At least 3-5 more press releases are about to be announced in the very near future.

1. Methotrexate
$63 million market
Just launched on 8/27/24

https://elite.irpass.com/profiles/investor/ResLibraryView.asp?ResLibraryID=137279&BzID=2258&g=939&Nav=0&LangID=1&s=0 (https://elite.irpass.com/profiles/investor/ResLibraryView.asp?ResLibraryID=137279&BzID=2258&g=939&Nav=0&LangID=1&s=0)

2. Codeine with acetaminophen
$47 million market
Launched on 10/7/24

https://elite.irpass.com/profiles/investor/ResLibraryView.asp?ResLibraryID=138878&BzID=2258&g=939&Nav=0&LangID=1&s=0

3. Record earnings conference call
11/14/24
Press release #1

ELTP approved drugs with pending launches:

4. Generic Percocet
oxycodone with acetaminophen
~$500 million market
Will launch 6-8 weeks after the codeine with acetaminophen launch
Press Release #2
As early as 11/18/24

5. Generic Norco
hydrocodone with acetaminophen
~$477 million market
Will launch 6-8 weeks after the oxycodone with acetaminophen launch
Press Release #3
As early as 12/30/24

6. Dolophine/Methadone
~$30 million market
Will launch 6-8 weeks after the hydrocodone with acetaminophen launch
Press Release #4
As early as 2/14/25

7. Pending approval:
Generic Vyvanse
~$5.1 billion market
This is the monster news that everyone is waiting for.
Hopefully the approvable positive press release will come out by November 2024.
Press Release #5

8. Launch of Generic Vyvanse
Press Release #6

9. Pending approval for launch:
Generic OxyContin
~$720 million market
Press release #7

10. Pending approval for launch:
Generic Vigabatrin
~$233 Million market
Press release #8

9. Pending BE equivalent study result:
Generic Concerta
~$1.2 billion market
Press release #9

10. Pending submittal:
Generic Requip XL or
Generic Mirapex ER
$12 Million market
Press release #10

$63 million - Methotrexate
+ $47 million - Codeine
+ $500 million - Percocet
+ $477 million - Norco
+ $30 million - Methadone
+ $720 million -OxyContin
+ $233 million - Vigabatrin
+ $12 million - Requip
= $2.081 billion

$2.081 billion
+ $5.1 billion Vyvanse
+ $1.2 billion Concerta
= $8.381 billion market

CEO Nasrat Hakim still holds 221,572,000 shares according to Yahoo.

https://finance.yahoo.com/quote/ELTP?p=ELTP

But according to this website below, he and Mika Pharma holds:

267,272,787 Mika Pharma
+ 221,572,397 Nasrat Hakim
= 488,845,184 total shares

https://www.secform4.com/insider-holders/1053369.html

ELTP Insider Holders & Insider Ownership - ELITE PHARMACEUTICALS INC

It is in his best interest to continue to provide the rocket fuel for ELTP.

Therefore, we can expect more higher revenue drugs in the pipeline soon for more BE studies since Elite now has money to do so.

Wouldn’t be great if Nasrat or Carter can say something like this on our next conference call,
“Our current EPS is $0.0191 per share and the current average P/E for a generic drug manufacturer is 36.45. Based on those two numbers, our stock price should be around $0.6962. However, our EPS will be significantly much higher soon, and ELTP share price could eventually be $6.962 with our target of $566 million per year in revenue.”

Good luck to all you longterm ELTP investors out there. We all will be well rewarded soon with financial freedom.

Fake King - Time to sell a few shares and reimburse this Credit Card Debt

synthetic shares - they do not show in your share count on Schwab - going for another tricky day

Between Mikah and Nasrat's shares, Nasrat has 500 Million shares - his only way to cash out/Exit is Buyout.

Read the transcript from Aug 15 - M&A back on the table

That was about 2 years ago.

We may see a new request from Nasrat to create a new valuation soon.

For Passive basher it is. morning.

Any complaints go to the fake king and ib_
Lol

Another actor if u ask me

With the help of the fake king who gave us a fake date for vyvanse approval to keep everyone in play and attract more investors. Knit picking my ask. Lol

The answer is Nasrat.

Nasrat and Mikah have almost 500 million shares. Together do you think for a second that he will let them win after all what he showed us what he can do?

He will get the buyer.

I had asked Dianne a while ago and that was her answer:
3) What is the current valuation of the company from an independent auditor ?

We do not have a current evaluation. The last time this was done is because it was needed when we put a poison pill in place. It is not something that is typically done unless there is a compelling reason to do so.

Between Mikah and Nasrat, it is more likely 500 Million shares

no punctuation? mmmm

-------
Just added more$$$$ why not at these prices

To buy back the same stock - you need to wait a day - if not it is a violation. They may let you do it on the platform but it is a violation. Fidelity blocks you.

Yes - you do. unless you are a day trader

Next 90 days - Life changing events...

November 18th 2024.

One more tool in our toolbox: all the filings for ELTP in the last 5 years...
https://www.sec.gov/edgar/search/#/q=ELTP&ciks=0001053369&entityName=ELITE%2520PHARMACEUTICALS%2520INC%2520%252FNV%252F%2520(ELTP)%2520(CIK%25200001053369)